Costing model for neonatal screening and diagnosis of haemoglobinopathies

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 79, Issue 3, 1998, Pages

  Cronin, E K ^a   Normand, C ^a   Henthorn, J S ^b   Hickman, M ^c   Davies, S C ^b,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c Brent and Harrow Health Authority   (United Kingdom)

^d NHS Executive North Thames   (United Kingdom)

Author keywords

Cost effectiveness; Haemoglobinopathies; Screening; Workload

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEMOGLOBINOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; SCREENING TEST; WORKLOAD;

EID: 0031773484     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.79.3.F161     Document Type: Article

References (29)

1. Department of Health. Report of a Working Party of the Standing Medical Advisory Committee on Sickle Cell, Thalassaemia, and other Haemoglobinopathies. London: HMSO, 1993.
2. Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, Davies SC. Mapping the prevalence of sickle cell and β thalassaemia in England: recommended rates for local service planning. (In press)
3. Tsevat J, Wong JB, Pauker SG, Steinberg MH. Neonatal screening for sickle cell disease: A cost-effectiveness analysis. J Pediatr 1991;118:546-54
4. Lane PA, Eckman JR. Cost effectiveness of neonatal screening for sickle cell disease. J Pediatr 1992;120:142-3.
5. Wright F. London after Tomlinson: Haemoglobinopathy Services in Kensington, Chelsea and Westminster. British Society of Haematology, London: 1993.
6. Sprinkle RH, Hynes DM, Konrad TK. Is universal neonatal hemoglobinopathy screening cost-effective? Arch Pediatr Adolesc Med 1994;148:461-9
7. US Department of Health & Human Services. Sickle Cell Disease: Screening, diagnosis, management, and counselling in newborns and infants: Clinical Practice Guideline. Washington, DC: HHS, 1993
8. Modell B, Anionwu EN. Guidelines for screening for haemoglobin disorders: service specifications for low and high prevalence DHAs. In: NHS Centre for Reviews and Dissemination/Social Policy Research Unit. Ethnicity and Health: Reviews of literature and Guidance for Purchasers in the Areas of Cardiovascular Disease, Mental Health, and Haemoglobinopathies. CRD Report 5, 1995:127-224.
9. Githens JH, Lane PA, McCurdy RS, Houston ML, McKinna JD, Cole DM. Newborn screening for hemoglobinopathies in Colorado. Am J Dis Child 1990;144:466-70.
10. Hurst, D. Northern California's experience. Pediatrics 1989,83 (Supplement):868-71.
11. Harris M, Eckman JR. Georgia's experience with newborn screening: 1981-1985. Pediatrics 1989;S3(Supplement): 858-60.
12. Griffiths P, Mann JR, Darbyshire PJ, Green A. Evaluation of eight and a half years of neonatal screening for haemoglobinopathics in Birmingham. BMJ 1988;296: 1583-5.
13. Consensus Conference. Newborn screening for sickle cell disease and other haemoglobinopathies. JAMA 1987,258:1205-9.
14. Adjaye N, Bain BJ, Steer P. Prediction and diagnosis of sickling disorders in neonates. Arch Dis Child 1989;64:39-43.
15. Horn M, Dick M, Frost B, et al. Neonatal screening for sickle cell diseases in Camberwell: results and recommendations of a two year pilot study. BMJ 1986;292:737-40.
16. Barton C, Watson A. Neonatal screening for haemoglobinopathies. BMJ 1988;297:200.
17. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 1986;314:1593-9.
18. Drummond MF. Principles of economic appraisal in health care. Oxford: Oxford University Press, 1980.
19. Sprinkle RH, Konrad TR. Is universal neonatal hemoglobinopathy screening cost-effective? Arch Pediatr Adolesc Med 1995;149:466-7.
20. Holland W, Stewart S. Screening in Health Care: Benefit or Bane? Oxford: Nuffield Provincial Hospitals Trust, 1990.
21. Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985;107:201-6.
22. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 1995;311:1600-2.
23. Rowley P, Huntzinger D. Newborn sickle cell screening. Am J Dis Child 1983;137:341-5.
24. Kinney T, Sawtschenko M, et al. Techniques' comparison and report of the North Carolina experience. Pediatrics 1989;83(Supplement):843-8.
25. Cairns J, Shackley P. Tries hard but could do better: a report on the economics of screening. Aberdeen: Health Economics and Research Unit, London, 1992.
26. Eastman JW, Wong R, Liao CL, Morales DR. Automated HPLC screening of newborns for sickle cell anemia and other hemoglobins. Clin Chem 1996;42:704-10.
27. Delahunty T. Convenient screening for hemoglobin variants by using the Diamat HPLC system. Clin Chem 1990;36:903-5.
28. Kleman KM, Vichinsky E, Lubin BH. Experience with newborn screening using isoelectric focusing. Pediatrics 1989;83(Supplement):852-4.
29. Huisman T. Usefulness of cation exchange high performance liquid chromatography as a testing procedure. Pediatrics 1989;83(Supplement):849-51.